The Technical Analyst
LianBio [LIAN]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
LianBio Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
0.00% $0.319
America/New_York / 4 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 34.47 mill |
| EPS: | -0.820 |
| P/E: | -0.390 |
| Earnings Date: | Mar 25, 2024 |
| SharesOutstanding: | 108.06 mill |
| Avg Daily Volume: | 0.960 mill |
| RATING 2024-04-03 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | ||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.390 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.07x |
| Company: PE -0.390 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.694 (117.51%) $0.375 |
| Date: 2024-03-23 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0360 - 0.562 ( +/- 87.96%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-01-02 | Gu Ehong | Sell | 1 731 | Ordinary Shares |
| 2024-04-09 | Gu Ehong | Sell | 17 889 | Ordinary Shares |
| 2024-02-15 | Poukalov Konstantin | Buy | 36 300 | Ordinary Shares |
| 2024-02-15 | Poukalov Konstantin | Sell | 19 218 | Ordinary Shares |
| 2024-02-15 | Poukalov Konstantin | Sell | 36 300 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 71.51 |
| Last 79 transactions |
| Buy: 50 859 501 | Sell: 7 434 951 |
Forecast:
16:00 - $0.333
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.333
Forecast 2: 16:00 - $0.333
Forecast 3: 16:00 - $0.333
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.319 (0.00% ) |
| Volume | 2.48 mill |
| Avg. Vol. | 0.960 mill |
| % of Avg. Vol | 258.20 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For LIAN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:15 | sell | $4.08 | N/A | Active |
|---|
LIAN
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn's disease; NX-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03, an eye solution for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
Latest Press Releases
2024-02-28 07:00:00 - Press Release
Lianbio Announces Voluntarily Delisting From Nasdaq
Shanghai, china and princeton, n.j., feb. 28, 2024 (globe newswire) -- lianbio (nasdaq: lian) (“lianbio” or the “company”), a biotechnology company dedicated to bringing innovative medicines to patients in china and other major asian markets, today announced that it has provided notification to the nasdaq stock market, inc. (“nasdaq”) of its intent to delist the company's american depositary shares (“adss”), each representing the right to receive one ordinary share of the company, from the nasdaq global market. lianbio expects to file a form 25 (notification of removal from listing) with the securities and exchange commission (the “sec”) and nasdaq relating to the voluntary delisting of its adss on or about march 11, 2024.
2024-02-13 07:00:00 - Press Release
Lianbio Announces Completion Of Strategic Review
Lianbio to commence the wind down of its operations, including sale of remaining assets and reduction in force, delisting from nasdaq and issuance of special cash dividend lianbio to commence the wind down of its operations, including sale of remaining assets and reduction in force, delisting from nasdaq and issuance of special cash dividend
2023-12-20 08:00:00 - Press Release
Lianbio Announces Departure Of Chief Financial Officer
Shanghai, china and princeton, n.j., dec. 20, 2023 (globe newswire) -- lianbio (nasdaq: lian), a biotechnology company dedicated to bringing innovative medicines to patients in china and other major asian markets, today announced that yi larson, chief financial officer, has resigned from lianbio to pursue other opportunities, effective december 19, 2023.
2023-12-19 16:05:00 - Press Release
Lianbio Announces Departure Of Chief Executive Officer
Shanghai, china and princeton, n.j., dec. 19, 2023 (globe newswire) -- lianbio (nasdaq: lian), a biotechnology company dedicated to bringing innovative medicines to patients in china and other major asian markets, today announced that yizhe wang, ph.d., chief executive officer has resigned from lianbio to pursue other opportunities.
2023-12-06 16:05:00 - Press Release
Lianbio's Board Of Directors Unanimously Determines Not To Pursue Unsolicited Proposal From Concentra Biosciences
Shanghai, china and princeton, n.j., dec. 06, 2023 (globe newswire) -- lianbio (nasdaq: lian), a biotechnology company dedicated to bringing innovative medicines to patients in china and other major asian markets, today announced that its board of directors (the “board”) unanimously determined not to pursue the unsolicited proposal from concentra biosciences, llc to acquire 100% of the equity of lianbio for $4.30 per share in cash, plus a contingent value right representing the right to receive 80% of the net proceeds payable from any license or disposition of lianbio's programs (the “proposal”).
Latest News
2024-03-15 08:40:47 - InvestorPlace
Why Is LianBio (LIAN) Stock Moving Today?
LianBio (NASDAQ: LIAN ) stock is moving on Friday and this is likely tied to the company's voluntary delisting of its shares from the Nasdaq Exchange. LianBio announced late last month plans to voluntarily delist shares of LIAN stock.
2023-11-08 13:31:29 - Zacks Investment Research
All You Need to Know About LianBio Sponsored ADR (LIAN) Rating Upgrade to Strong Buy
LianBio Sponsored ADR (LIAN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
2023-10-27 08:32:43 - The Motley Fool
Why LianBio Stock Is Shooting Through the Roof This Week
LianBio has entered into a major deal with Bristol Myers Squibb. Bristol Myers will pay $350 million for the rights to develop and commercialize LianBio's mavacamten treatment in select Asian countries and territories.
2023-10-26 15:06:14 - PennyStocks
3 Penny Stocks To Buy For Under $5, Are They Worth It?
Penny stocks are defined as stocks trading for under $5. They typically include start-up or emerging-growth stage companies starting from the grassroots.
2023-10-24 13:48:58 - InvestorPlace
Why Is LianBio (LIAN) Stock Up 130% Today?
Shares of LianBio (NASDAQ: LIAN ) — which focuses on “developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries” — are soaring on Tuesday. Earlier this morning, the company announced a key agreement with Bristol-Myers Squibb (NYSE: BMY ) regarding exclusive rights to a cardiovascular therapeutic.
2023-10-24 12:40:16 - The Motley Fool
Why LianBio Stock Is Skyrocketing Today
LianBio entered into a deal to give Bristol Myers Squibb exclusive rights for mavacemten in China and other Asian markets. The small drugmaker will receive $350 million.
2023-10-24 09:02:45 - PennyStocks
4 Hot Penny Stocks To Watch With Big News This Week
Whether you're trading penny stocks or stocks over $100, the goal is the same. You want to find opportunities as early as possible and capitalize.
2023-06-01 16:15:00 - GlobeNewsWire
LianBio to Participate in Upcoming Investor Conferences
SHANGHAI, China and PRINCETON, N.J., June 01, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that members of the management team will participate in the following upcoming investor conferences:
2022-12-20 12:02:16 - Zacks Investment Research
LianBio (LIAN) Up After Pfizer Opts in Rights to RSV Drug in China
As a result of Pfizer's (PFE) opt-in for LianBio's (LIAN) rights to develop RSV therapeutic candidate sisunatovir in Greater China, the latter is eligible to receive potential royalties and milestone payments.
2022-12-19 09:33:00 - PennyStocks
Penny Stocks To Buy Now? 6 To Watch With Big News Today
